Left Menu
Development News Edition

EIB signs €40m loan agreement with Swedish biotech firm Oncopeptides

Each year, approximately 3 in every 10,000 people are diagnosed with multiple myeloma, for which there is no cure.

EIB | Stockholm | Updated: 14-10-2020 22:36 IST | Created: 14-10-2020 22:36 IST
EIB signs €40m loan agreement with Swedish biotech firm Oncopeptides
Oncopeptides’ Melflufen is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumour cells. Image Credit: Videoblocks

The European Investment Bank (EIB) has signed a €40 million (SEK 416m) loan agreement with Swedish biotech company Oncopeptides AB. The financing will support research, including phase 3 clinical studies of the lead candidate melflufen, and the expansion of the company. The EU bank's loan is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe under which the EIB and the European Commission are working together as strategic partners, with the EIB's financing operations boosting the competitiveness of the European economy.

Each year, approximately 3 in every 10,000 people are diagnosed with multiple myeloma, for which there is no cure. Therefore, a key focus of treatment is extending and improving the quality of life for patients. Oncopeptides' Melflufen is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumour cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. A New Drug Application of Melfufen has been granted priority review by the U.S. Food and Drug Administration, FDA, for treatment of patients with multiple myeloma. A target date for the review is set to February 28, 2021. Oncopeptides is currently conducting one clinical phase 3 study and six clinical phases 2 studies.

EIB Vice-President Thomas Östros noted: "This is the kind of project that the Investment Plan for Europe was set up to support. There is still a market gap when it comes to what is called "non-dilutive growth capital", allowing innovative, fast-growing EU-based SMEs to grow without giving up ownership of their ideas or company. This quasi-equity instrument allows us to support EU in-house knowledge and expertise to flourish, we're very happy to get behind yet another innovative Swedish company that has ground-breaking plans for the future."

"As the company is approaching potential commercialization of its lead product melflufen, several new financing options become available. The EIB facility is a flexible solution that can be drawn upon with limited dilution for the shareholders, which is highly valuable to the company in this transition phase. We are grateful for the support from the EIB and look forward to working together through the continued expansion of Oncopeptides", says Anders Martin-Löf, CFO of Oncopeptides.

European Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, said: "Investment in research and innovation is crucial towards achieving our goal to beat cancer, contributing to the development of effective health and care tools for the prevention, early diagnosis and successful treatment of the disease. This is why we are setting up a mission to fight cancer as part of the future Horizon Europe programme. By joining efforts across Europe, we will ensure that more people will live without cancer in the future while increasing quality of life for those affected."


TRENDING

OPINION / BLOG / INTERVIEW

Turbulence surrounding tobacco control in Ghana

... ...

Smart healthcare: IoT redefining the way healthcare is delivered

As the world is embracing the new wave of digitalization triggered by the pandemic and the arrival of 5G, the adoption of IoT devices will further boom. With adoption set to soar, IoT security issues and other challenges cant be ignored any...

Refugee compassion and response: Ideas to mitigate disasters now and in their future

Their homeland becomes a forbidden territory for them and more likely than not, their journey to foreign soil is no less traumatizing, not to say deadly. It is crucial to help refugees live a life of dignity and purpose....

Inadequate water infrastructure causes a tidal wave of coronavirus in rural Alaska

... ...

Videos

Latest News

We must look to leverage FTAs with countries having transparent trading mechanisms: Goyal

Free trade agreements are good for the nation and India must look to leverage these pacts with countries having transparent trading mechanisms and business systems, Commerce and Industry Minister Piyush Goyal said on Saturday. He said India...

PM reviews vaccine development, manufacturing at 3 facilities

Prime Minister Narendra Modi on Saturday visited Ahmedabad, Hyderabad and Pune to review the development and manufacturing process of coronavirus vaccines at facilities in these cities. He visited the Zydus Biotech Park in Ahmedabad, Bharat...

BoE's Haldane sees inflation risks as economies bounce back

Bank of England Chief Economist Andy Haldane said inflation could rise by more than expected as progress on COVID-19 vaccines and huge amounts of stimulus raised the chances of a swift economic bounce-back.As the economic recovery gathers p...

UK appoints vaccines minister to oversee COVID inoculations

The British government appointed a vaccines minister on Saturday as it prepares to inoculate millions of people against the coronavirus, potentially starting within days. Prime Minister Boris Johnson said Conservative lawmaker Nadhim Zahawi...

Give Feedback